TY - JOUR
T1 - Dosing pole recommendations for lymphatic filariasis elimination
T2 - A height-weight quantile regression modeling approach
AU - Goss, Charles W.
AU - O’Brian, Katiuscia
AU - Dubray, Christine
AU - Fischer, Peter U.
AU - Hardy, Myra
AU - Jambulingam, Purushothaman
AU - King, Christopher L.
AU - Laman, Moses
AU - Lemoine, Jean Frantz
AU - Robinson, Leanne J.
AU - Samuela, Josaia
AU - Subramanian, Swaminathan
AU - Supali, Taniawati
AU - Weil, Gary J.
AU - Schechtman, Kenneth B.
N1 - Funding Information:
This project was funded by the Bill & Melinda Gates Foundation (https://www.gatesfoundation.org/) and by the Coalition for Operational Research on Neglected Tropical Diseases (https://www.ntdsupport.org/cor-ntd) that is funded by the Gates Foundation, USAID, and DFID (UK). Author Gary J. Weil is the PI of the project, and work by all of the authors who participated in the project was funded by these funding agencies. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors acknowledge the people who agreed to participate in the study and the efforts of field research teams in five countries who collected height and weight data in the course of the DOLF IDA Safety Study. The opinions expressed in this article are the author's own and do not reflect the view of the Centers for Disease Control and Prevention, the Department of Health and Human Services, or the United States government.
Publisher Copyright:
© 2019, Public Library of Science. All rights reserved.
PY - 2019/7
Y1 - 2019/7
N2 - Background: The World Health Organization (WHO) currently recommends height or age-based dosing as alternatives to weight-based dosing for mass drug administration lymphatic filariasis (LF) elimination programs. The goals of our study were to compare these alternative dosing strategies to weight-based dosing and to develop and evaluate new height-based dosing pole scenarios. Methodology/Principal findings: Age, height and weight data were collected from >26,000 individuals in five countries during a cluster randomized LF clinical trial. Weight-based dosing for diethylcarbamazine (DEC; 6 mg/kg) and ivermectin (IVM; 200 ug/kg) with tablet numbers derived from a table of weight intervals was treated as the “gold standard” for this study. Following WHO recommended age-based dosing of DEC and height-based dosing of IVM would have resulted in 32% and 27% of individuals receiving treatment doses below those recommended by weight-based dosing for DEC and IVM, respectively. Underdosing would have been especially common in adult males, who tend to have the highest LF prevalence in many endemic areas. We used a 3-step modeling approach to develop and evaluate new dosing pole cutoffs. First, we analyzed the clinical trial data using quantile regression to predict weight from height. We then used weight predictions to develop new dosing pole cutoff values. Finally, we compared different dosing pole cutoffs and age and height-based WHO dosing recommendations to weight-based dosing. We considered hundreds of scenarios including country- and sex-specific dosing poles. A simple dosing pole with a 6-tablet maximum for both DEC and IVM reduced the underdosing rate by 30% and 21%, respectively, and was nearly as effective as more complex pole combinations for reducing underdosing. Conclusions/Significance: Using a novel modeling approach, we developed a simple dosing pole that would markedly reduce underdosing for DEC and IVM in MDA programs compared to current WHO recommended height or age-based dosing.
AB - Background: The World Health Organization (WHO) currently recommends height or age-based dosing as alternatives to weight-based dosing for mass drug administration lymphatic filariasis (LF) elimination programs. The goals of our study were to compare these alternative dosing strategies to weight-based dosing and to develop and evaluate new height-based dosing pole scenarios. Methodology/Principal findings: Age, height and weight data were collected from >26,000 individuals in five countries during a cluster randomized LF clinical trial. Weight-based dosing for diethylcarbamazine (DEC; 6 mg/kg) and ivermectin (IVM; 200 ug/kg) with tablet numbers derived from a table of weight intervals was treated as the “gold standard” for this study. Following WHO recommended age-based dosing of DEC and height-based dosing of IVM would have resulted in 32% and 27% of individuals receiving treatment doses below those recommended by weight-based dosing for DEC and IVM, respectively. Underdosing would have been especially common in adult males, who tend to have the highest LF prevalence in many endemic areas. We used a 3-step modeling approach to develop and evaluate new dosing pole cutoffs. First, we analyzed the clinical trial data using quantile regression to predict weight from height. We then used weight predictions to develop new dosing pole cutoff values. Finally, we compared different dosing pole cutoffs and age and height-based WHO dosing recommendations to weight-based dosing. We considered hundreds of scenarios including country- and sex-specific dosing poles. A simple dosing pole with a 6-tablet maximum for both DEC and IVM reduced the underdosing rate by 30% and 21%, respectively, and was nearly as effective as more complex pole combinations for reducing underdosing. Conclusions/Significance: Using a novel modeling approach, we developed a simple dosing pole that would markedly reduce underdosing for DEC and IVM in MDA programs compared to current WHO recommended height or age-based dosing.
UR - http://www.scopus.com/inward/record.url?scp=85070789875&partnerID=8YFLogxK
U2 - 10.1371/journal.pntd.0007541
DO - 10.1371/journal.pntd.0007541
M3 - Article
C2 - 31314753
AN - SCOPUS:85070789875
SN - 1935-2727
VL - 13
JO - PLoS Neglected Tropical Diseases
JF - PLoS Neglected Tropical Diseases
IS - 7
M1 - e0007541
ER -